Sign in
Taking peoplePhase 3

A study to evaluate the immune response and safety of a vaccine against influenza in adults 18-64 years of age

Key facts

Who runs it
GlaxoSmithKline Biologicals
Where
Belgium and Germany8 sites in 2 countriesChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
1,500 people, planned
Started
16 Oct 2026
Expected to end
9 Jul 2027
Type of study
Interventional
Record updated
6 October 2026

Who can take part

Age
18 years to 64 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiary, return for follow-up visits, attendance to study contacts, and ability to access and utilize a phone or other electronic communications) independently or with the assistance of a caregiver
  • Written or witnessed (physically or digitally) informed consent obtained from the participant/LAR(s) of the participant prior to performance of any study-specific procedure
  • Healthy participants or medically stable patients as established by medical history and clinical examination. Participants with chronic medical conditions with or without specific treatment (e.g., chronic metabolic, cardiac, pulmonary, renal, hepatic, neurologic, and hematologic diseases) are allowed to participate in this study if considered by the investigator as medically stable. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during 3 months before enrollment
  • A male or female participant between and including 18 to 64 YOA at the time of the study intervention administration
  • For further inclusion criteria, kindly refer to the protocol (Section 5.1)

Who cannot take part

  • Administration of an influenza vaccine in the period starting 180 days before the study intervention administration or planned administration prior to Visit 2 during the study
  • History of test confirmed influenza infection within 180 days prior to study intervention administration
  • Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune modifying treatments at any time up to the end of the study. • Up to 90 days prior to the study intervention administration: o For systemic corticosteroids: prednisone equivalent ≥20 mg/day for >14 days. Inhaled, intra articular/intra-bursal, and topical steroids are allowed. o Long-acting immune modifying drugs including, among others, immunotherapy (e.g., TNF inhibitors), monoclonal antibodies, antitumoral medication
  • History of myocarditis or pericarditis considered causally associated with the administration of an mRNA vaccine
  • Acute or unstable chronic conditions [clinically significant pulmonary, cardiovascular, hepatic, metabolic/endocrine disorders, renal functional abnormality, or psychiatric conditions], as determined by medical history and clinical examination
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required). HIV infected individuals may be enrolled if they have been stable on antiretroviral therapy for the past 6 consecutive months, i.e., their treatment has not been modified, their CD4 cell count is ≥200/mm³ and their viral load has been undetectable (i.e., HIV-RNA < 50 copies/mL)
  • For further exclusion criteria, kindly refer to the protocol (Section 5.2)

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

To demonstrate the non-inferiority of the investigational study intervention in adults 18-64 YOA as compared to adults aged 65 YOA and older in study FLU SV MRNA-006 in terms of humoral immune response to the HA and NA antigens. To demonstrate the non-inferiority of the investigational study intervention as compared to Flu D-TIV in adults 18-64 YOA in terms of humoral immune response to the HA antigens. To evaluate the safety and reactogenicity of the study interventions.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A phase 3 randomized, observer-blind, controlled study to evaluate the immunogenicity, reactogenicity and safety of an mRNA-based seasonal influenza vaccine, in adults 18-64 years of age
Criteria questions
Built from 2026-526925-17-00, who can take part
Record updated
6 October 2026